Strategic Acquisition Drives XTL Biopharmaceuticals (XTLB) To Nearly Double
Strategic Acquisition Drives XTL Biopharmaceuticals (XTLB) To Nearly Double
During the current trading session, the shares of XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) are experiencing a notable surge of 98.06%, culminating in a valuation of $2.04. This remarkable upswing in XTLB shares is directly attributable to a recent strategic acquisition move.
在本交易時段中，XTL生物製藥有限公司（納斯達克股票代碼：XTLB）的股票顯著上漲了98.06％，最終估值爲2.04美元。XTLB股價的顯著上漲直接歸因於最近的戰略收購舉措。
XTL Biopharmaceuticals (XTLB) announced today its formal agreement with THE SOCIAL PROXY Ltd., delineated within a binding term sheet. The Social Proxy stands as an avant-garde entity specializing in web data solutions, crafting and empowering a distinctive ethical, IP-centric proxy and data extraction platform tailored for AI & BI Applications at scale.
XTL Biopharmaceuticals（XTLB）今天宣佈與THE SOCIAL PROXY Ltd.簽訂的正式協議，該協議載於一份具有約束力的條款表中。Social Proxy是一家前衛實體，專門提供網絡數據解決方案，爲大規模人工智能和商業智能應用量身定製，精心打造和支持以知識產權爲中心的獨特道德代理和數據提取平台。
Pursuant to the Term Sheet, XTLB intends to acquire the entirety of Social Proxy's issued and outstanding share capital on a fully diluted basis. This acquisition will be executed through a private placement, wherein the Company will issue a certain number of ADS's representing 44.6% of its issued and outstanding share capital post-issuance, alongside a payment of US$430,000 to Social Proxy's shareholders.
根據條款表，XTLB打算在全面攤薄的基礎上收購Social Proxy的全部已發行和流通股本。此次收購將通過私募方式執行，其中公司將發行一定數量的ADS，佔其發行後已發行和流通股本的44.6％，同時向Social Proxy的股東支付43萬美元。
Furthermore, as a component of the Transaction, Social Proxy's shareholders will receive additional warrants, exercisable upon meeting specific financial benchmarks within a three-year timeframe subsequent to the Transaction's closure. As part of XTL Biopharmaceuticals' overarching strategy, the proposed transaction complements its asset portfolio with high growth prospects.
此外，作爲交易的一部分，Social Proxy的股東將獲得額外的認股權證，這些認股權證可在交易結束後的三年時間內達到特定的財務基準後行使。作爲XTL Biopharmaceuticals總體戰略的一部分，擬議的交易以高增長前景補充了其資產組合。
A private placement commitment of US$1,500,000 has been obtained by the Company to strengthen its financial position and expedite the transaction. In exchange for their investment, investors will receive 1,500,000 units, each consisting of one ADS and one warrant that can be exercised for five years after issuance at a price of US$1.20 per warrant.
該公司已獲得150萬美元的私募承諾，以鞏固其財務狀況並加快交易。作爲投資的交換，投資者將獲得1,500,000個單位，每個單位由一份ADS和一份認股權證組成，可以在發行後的五年內以每份認股權證1.20美元的價格行使。
Due to the involvement of Mr. Alexander Rabinovich, a director and 23.5% shareholder of the company, the investment is subject to shareholder approval. Following the acquisition, Social Proxy will operate as a fully-owned subsidiary of XTL Biopharmaceuticals, and its shareholders will have the authority to select two of the company's possible seven board of directors representatives.
由於公司董事兼23.5％股東亞歷山大·拉比諾維奇先生的參與，該投資需要股東批准。收購後，Social Proxy將作爲XTL Biopharmaceuticals的全資子公司運營，其股東將有權從公司可能的七名董事會代表中選出兩名。
譯文內容由第三人軟體翻譯。